Supernus, Inc. (SUPN) stock
Close on Nov 11, 2026Market cap $3.48BP/E 8.2Yield –
Supernus, Inc. grew revenue 16.3% to $1.37B over the twelve months to Sep 30, 2026. Operating income rose 145.8% to $558.00M, moving the operating margin from 19.2% to 40.6%. Free cash flow was $31.00M, down 73.9% from a year earlier. At the latest close the market valued the company at $3.48B, 8.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.48B
- P/E ratio
- 8.2
- Price to sales
- 2.53
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 0.89%
Fundamentals
- Revenue
- $1.37B
- Net income
- $450.00M
- EPS, diluted
- $3.57
- Free cash flow
- $31.00M
- Book value per share
- -$0.49
- Diluted shares
- 122M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $28.75
- Open
- $28.75
- Day's range
- $28.67 – $29.66
- Volume
- 3,072,573
- Average volume (20 days)
- 3,683,490
- Beta (5 years)
- 0.69
- 52-week range
- $25.92 – $42.81
- RSI (14 days)
- 39.2
- Volatility (1 year)
- 40.9%
- Relative volume
- 1.23×
- WACC
- 7.8%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SUPN | S&P 500 | Difference | SUPN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.9% | -2.4% | +8.3 pts | ||
| 3 months | -1.2% | -1.2% | −0.1 pts | ||
| Year to date | +5.8% | +12.3% | −6.5 pts | ||
| 1 year | +22.2% | +12.4% | +9.7 pts | ||
| 3 years | +137.7% | +78.8% | +58.9 pts | +33.5% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Supernus filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Results
- Results
About Supernus
Pharmaceutical Preparations
Indivior Pharmaceuticals, Inc. develops and commercializes prescription medicines focused on treating opioid use disorder and related conditions. Its principal commercial offerings include SUBLOCADE, an extended-release monthly injectable suspension, and SUBOXONE Film, a sublingual formulation combining buprenorphine and naloxone. The company also provides SUBUTEX sublingual tablets in select international markets. Through these pharmacotherapies, Indivior serves individuals diagnosed with opioid dependence as well as healthcare providers and clinical systems managing substance use recovery programs.
Company profile, executives and historySupernus stock: common questions
What is Supernus's stock price?
SUPN closed at $29.45 on Nov 11, 2026, up 2.43% on the day. Over the past 52 weeks it traded between $25.92 and $42.81.
What is Supernus's market cap?
Supernus was worth $3.48B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SUPN's P/E ratio?
SUPN trades at 8.2 times earnings, based on diluted earnings per share of $3.57 over the twelve months to Sep 30, 2026.
How much revenue does Supernus make?
Supernus reported revenue of $1.37B for the twelve months to Sep 30, 2026, up 16.3% from a year earlier.
Does Supernus pay a dividend?
No. Supernus has not paid a cash dividend over the last twelve months.
When does Supernus report earnings next?
Supernus is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SUPN stock performed over the past year?
Including dividends, SUPN returned +22.2% over the past year, against +12.4% for the S&P 500.
Who are Supernus's competitors?
Companies most similar to Supernus by business, industry and size include ALKS, ACAD, COLL, ANIP, INSM.
See a number that looks wrong?